The Q32 Bio Inc. (QTTB) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K that highlight material events. Q32 Bio’s filings reflect its status as a Nasdaq-listed clinical stage biotechnology company focused on alopecia areata and other autoimmune and inflammatory diseases.
Recent Form 8-K filings referenced by Q32 Bio include reports furnished under Item 2.02 for quarterly financial results and corporate updates, and under Item 8.01 for other events such as clinical trial milestones. For example, the company has filed 8-Ks in connection with press releases announcing financial results for specific quarters, as well as an 8-K describing the completion of enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial of bempikibart for alopecia areata. Another 8-K details leadership changes under Item 5.02, including the resignation of a Chief Medical Officer and the appointment of an interim Chief Medical Officer.
Q32 Bio’s 8-K filings also confirm that its common stock, with a par value of $0.0001 per share, is registered pursuant to Section 12(b) of the Exchange Act and trades on Nasdaq under the symbol QTTB. The filings typically attach press releases as exhibits, which are incorporated by reference where specified, and clarify whether the information is being furnished rather than filed for purposes of Section 18 of the Exchange Act.
On Stock Titan, these SEC documents are updated as they become available from EDGAR and are paired with AI-powered summaries that explain the key points in accessible language. Users can quickly see which filings relate to financial results, clinical trial updates, leadership changes, or other corporate events, and can review the underlying forms and exhibits for more detail.
Q32 Bio Inc. director David S. Grayzel reported a grant of stock options on January 15, 2026 under the company’s 2024 Stock Option and Incentive Plan and non-employee director compensation policy. The award covers 16,363 options with an exercise price of $2.75 per share.
The options vest in four equal quarterly installments on the last day of each calendar quarter, conditioned on his continued service, and were elected in lieu of cash retainer fees. The filing notes the grant was initially omitted due to administrative oversight. Any proceeds from sales of shares issued on exercise will be transferred to Atlas Venture Life Science Advisors, LLC, and Grayzel disclaims beneficial ownership except for any pecuniary interest.
Q32 Bio Inc. reported that director Sven Ante Lundberg received a grant of stock options on January 15, 2026. The award covers 20,363 stock options to buy Q32 Bio common stock at an exercise price of $2.75 per share.
The options were granted under the company’s 2024 Stock Option and Incentive Plan and its non-employee director compensation policy, reflecting Lundberg’s election to receive options instead of cash retainer fees. The grant vests in four equal quarterly installments, each at the end of a calendar quarter, conditioned on continued board service. The filing notes the award was initially not reported due to administrative oversight.
Q32 Bio (QTTB) reported third‑quarter 2025 results showing sharply lower operating spend and a narrower loss, alongside a reduced cash balance and an equity deficit. Cash and cash equivalents were $49.0 million as of September 30, 2025, down from $78.0 million at year‑end. Total assets were $57.8 million against total liabilities of $76.2 million, resulting in stockholders’ equity (deficit) of $(18.4) million.
Quarterly net loss was $7.4 million versus $17.6 million a year ago as research and development fell to $3.6 million from $14.3 million, with general and administrative at $4.0 million. For the nine months, net loss totaled $27.9 million, and operating cash outflow was $27.4 million. The company expects its cash to fund operations for at least one year from the financial statement issuance date. Management executed a February 2025 restructuring to prioritize bempikibart in AA, discontinued the Phase 2 ADX‑097 renal basket trial, and recorded $0.9 million of severance costs. The company also completed the sale of its 10% OXB (US) LLC interest for $2.5 million and eliminated the related CVR liability by quarter end.
Q32 Bio Inc. reported that it announced its financial results for the quarter ended September 30, 2025 and provided a corporate update. The company furnished a press release as Exhibit 99.1 to an Item 2.02 current report.
The information in the report, including Exhibit 99.1, is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act, nor incorporated by reference unless specifically stated. Q32 Bio’s common stock trades on the Nasdaq Global Market under the symbol QTTB.
Q32 Bio (QTTB) reported a director stock option grant on a Form 4. The director was awarded 53,521 stock options at an exercise price of $2.80 per share on 10/23/2025, expiring on 10/22/2035. The options vest in full on the earlier of October 23, 2026 or the date of the company’s next annual meeting of stockholders, subject to continued service. Following the transaction, the director beneficially owns 53,521 derivative securities, held directly.
Q32 Bio (QTTB) reported a director’s stock option grant on a Form 4. On 10/23/2025, the director acquired 53,521 stock options (Code A) with an exercise price of $2.80 per share, expiring on 10/22/2035. The options vest in full on the earlier of October 23, 2026 or the date of the company’s next annual stockholder meeting, contingent on continued service. Following this transaction, the director beneficially owns 53,521 derivative securities, held directly. The price of the derivative security was listed as $0.00.
Q32 Bio (QTTB) reported a director stock option grant. On 10/23/2025, the reporting person received a stock option for 53,521 shares at an exercise price of $2.80 per share. Following the transaction, 53,521 derivative securities were beneficially owned directly.
The option vests in full upon the earlier of October 23, 2026 or the issuer’s next annual meeting of stockholders, subject to continued service, and expires on 10/22/2035. The filing lists the grant as an acquisition.
Q32 Bio Inc. (QTTB) reported a director stock option grant on a Form 4. The filing lists a stock option (right to buy) for 53,521 shares at an exercise price of $2.80, dated 10/23/2025, with an expiration on 10/22/2035. The option acquisition is recorded at $0.00 for the derivative security.
Vesting occurs in full on the earlier of October 23, 2026 or the issuer’s next annual meeting of stockholders, subject to continued service. The ownership form is listed as Direct. A footnote states the reporting person is obligated, pursuant to an agreement, to transfer any securities or economic benefits from such awards to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will ensure they are provided to OrbiMed Private Investments VII, LP.
Q32 Bio (QTTB) reported a director stock option grant on a Form 4. On 10/23/2025, the director was awarded 53,521 stock options at an exercise price of $2.80 per share. The options expire on 10/22/2035 and will vest in full on the earlier of 10/23/2026 or the company’s next annual stockholder meeting, subject to continued service. Following the grant, the director beneficially owns 53,521 derivative securities directly.
Q32 Bio (QTTB) reported a director equity grant on a Form 4. On 10/23/2025, the director was granted a stock option for 53,521 shares at an exercise price of $2.8 per share, expiring on 10/22/2035. The option vests in full upon the earlier of October 23, 2026 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continued service. Following the grant, 53,521 derivative securities were beneficially owned in direct form.
The filing notes that proceeds of any sale of shares issued upon exercise will be transferred to Atlas Venture Life Science Advisors, LLC, and the Reporting Person disclaims ownership except to the extent of any pecuniary interest.